|Phase IV||Natural history/Epidemiology||Approved-not yet active||Any age||Pharmaceutical / Industry||15246|
The objective of this Non-Interventional study is to evaluate the effectiveness & safety of Nexavar in advanced Renal Cell Carcinoma (RCC) patients under daily-life treatment conditions based on age of the patient (older (age >70 years) and younger patients (age <70 years). Specifically investigated are the tumor status, duration of Nexavar ® treatment (number of cycles) and incidence of Hand foot Skin Reaction.
- Patients with diagnosis of advanced Renal Cell Carcinoma (RCC) and decision taken by the investigator to prescribe Sorafenib
- Exclusion criteria must be read in conjunction with the local product information.
Trial Lead Organizations/Sponsors
|Bayer Study Director||Study Director|
|Bayer Clinical Trials Contact|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01353794
ClinicalTrials.gov processed this data on November 17, 2013
Back to Top